[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100546734":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":36,"locations":42,"responsibleParty":59,"collaborators":26,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":63,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":26,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":26,"overallStatus":44,"whyStopped":26,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"First Affiliated Hospital of Wenzhou Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"DTS group","EXPERIMENTAL","Patients undergo Dual-port Trans-subclavian Thyroid Endoscopic Surgery (DTS)",[13],"Procedure: Dual-port Trans-subclavian Thyroid Endoscopic Surgery (DTS).",{"label":15,"type":16,"description":17,"interventionNames":18},"COT group","ACTIVE_COMPARATOR","Patients undergo conventional open thyroidectomy (COT)",[19],"Procedure: Conventional open thyroidectomy (COT)",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"PROCEDURE","Dual-port Trans-subclavian Thyroid Endoscopic Surgery (DTS).","An innovative surgical approach, Dual-port Trans-subclavian Thyroid Endoscopic Surgery (DTS), presents a unique dual-port endoscopic technique for thyroidectomy. DTS significantly reduces postoperative hospital stay, emphasizing its potential for accelerated patient recovery compared to COT.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Conventional open thyroidectomy (COT)","open thyroidectomy with traditional collar incisions",[15],[32],{"name":33,"affiliation":34,"role":35},"Jiashu Wu, Profe","The first hospital of Wenzhou Medical University","PRINCIPAL_INVESTIGATOR",[37],{"name":38,"role":39,"phone":40,"phoneExt":26,"email":41},"Chun Jin, Professor","CONTACT","86-13858707259","845095442@qq.com",[43],{"facility":5,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"RECRUITING","Wenzhou","Zhejiang","325000","China","CN",{"type":51,"coordinates":52},"Point",[53,54],120.66682,27.99942,{"lat":54,"lon":53},[57],{"name":38,"role":39,"phone":58,"phoneExt":26,"email":41},"13858707259",{"type":60,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100546734","dual-port-trans-subclavian-thyroid-endoscopic-surgery-100546734",false,"NCT06398795","Dual-port Trans-subclavian Thyroid Endoscopic Surgery","Dual-port Trans-subclavian Thyroid Endoscopic Surgery - an Exploration of Cavity Construction in Situ Heralds a New Approach Choice","DTS","Inclusion Criteria:\n\n* Thyroid cancer or benign thyroid tumors\n* Patients with a demand for incisional cosmetic improvement\n\nExclusion Criteria:\n\n* Patients with thyroid cancer larger than 2 cm\n* benign tumors larger than 5 cm\n* Patients with severe underlying diseases\n* Patients with chronic kidney disease,\n* Patients with autoimmune diseases\n* Patients with rheumatoid arthritis","ALL","18 Years","90 Years",{"count":73,"type":74},300,"ESTIMATED","INTERVENTIONAL",[77],"NA","This is a prospective, single-center, open-label, non-randomized controlled real-world study aimed at exploring a novel approach to cavity construction for thyroid endoscopic surgery. The study seeks to evaluate its effectiveness and safety while accumulating further evidence-based medical data.\n\nThree hundred patients with thyroid tumors were divided into an experimental group (150 cases receiving a new endoscopic thyroid surgery technique, namely, dual-port trans-subclavian thyroid endoscopic surgery) and a control group (150 cases undergoing traditional open thyroid surgery) according to their treatment intention. Laboratory and medical data from specified follow-up points are collected, and adverse events are recorded detailly.\n\nThe primary efficacy endpoint is a comparison of surgical complications between the two treatment groups. Secondary endpoints include: (1) levels of IL-2, IL-4, IL-6, IL-10, TNF-α, INF-γ, renin, angiotensin II, and aldosterone preoperatively and on the second day postoperatively; (2) NRS scores on the first day postoperatively; (3) length of hospital stay, duration of surgery, total treatment cost, and postoperative drainage volume; and (4) assessment of wound satisfaction during a three-month follow-up visit.\n\nSafety assessments include adverse events, vital signs, and pathological examinations.",[80,81],"Thyroid Neoplasms","Endoscopic Surgery","2024-12-29",{"date":84,"type":85},"2024-12-31","ACTUAL",{"date":87,"type":85},"2022-09-01",{"date":89,"type":74},"2026-12-31",{"name":5,"class":6},1]